Intracellular acidity impedes KCa3.1 activation by Riluzole and SKA-31.

KCa3.1 Riluzole SKA-31 acidity cancer ion channels

Journal

Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923

Informations de publication

Date de publication:
2024
Historique:
received: 01 02 2024
accepted: 05 03 2024
medline: 19 4 2024
pubmed: 19 4 2024
entrez: 19 4 2024
Statut: epublish

Résumé

The unique microenvironment in tumors inhibits the normal functioning of tumor-infiltrating lymphocytes, leading to immune evasion and cancer progression. Over-activation of KCa3.1 using positive modulators has been proposed to rescue the anti-tumor response. One of the key characteristics of the tumor microenvironment is extracellular acidity. Herein, we analyzed how intra- and extracellular pH affects K Whole-cell patch-clamp was used to measure KCa3.1 currents either in activated human peripheral lymphocytes or in CHO cells transiently transfected with either the H192A mutant or wild-type hKCa3.1 in combination with T79D-Calmodulin, or with KCa2.2. We found that changes in the intra- and extracellular pH minimally influenced the KCa3.1-mediated K Based on our data we conclude that KCa3.1 currents are not sensitive the either the intracellular or the extracellular pH in the physiological and pathophysiological range. However, intracellular acidosis in T cells residing in the tumor microenvironment could hinder the potentiating effect of KCa3.1 positive modulators administered to boost their activity. Further research is warranted both to clarify the molecular interactions between the modulators and KCa3.1 at different intracellular pH conditions and to define whether this loss of potency can be observed in cancer models as well.

Sections du résumé

Background UNASSIGNED
The unique microenvironment in tumors inhibits the normal functioning of tumor-infiltrating lymphocytes, leading to immune evasion and cancer progression. Over-activation of KCa3.1 using positive modulators has been proposed to rescue the anti-tumor response. One of the key characteristics of the tumor microenvironment is extracellular acidity. Herein, we analyzed how intra- and extracellular pH affects K
Methods UNASSIGNED
Whole-cell patch-clamp was used to measure KCa3.1 currents either in activated human peripheral lymphocytes or in CHO cells transiently transfected with either the H192A mutant or wild-type hKCa3.1 in combination with T79D-Calmodulin, or with KCa2.2.
Results UNASSIGNED
We found that changes in the intra- and extracellular pH minimally influenced the KCa3.1-mediated K
Conclusion UNASSIGNED
Based on our data we conclude that KCa3.1 currents are not sensitive the either the intracellular or the extracellular pH in the physiological and pathophysiological range. However, intracellular acidosis in T cells residing in the tumor microenvironment could hinder the potentiating effect of KCa3.1 positive modulators administered to boost their activity. Further research is warranted both to clarify the molecular interactions between the modulators and KCa3.1 at different intracellular pH conditions and to define whether this loss of potency can be observed in cancer models as well.

Identifiants

pubmed: 38638868
doi: 10.3389/fphar.2024.1380655
pii: 1380655
pmc: PMC11024243
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1380655

Informations de copyright

Copyright © 2024 Cozzolino and Panyi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Références

Pflugers Arch. 2003 Oct;447(1):44-54
pubmed: 12920598
Cell Death Dis. 2022 Oct 27;13(10):902
pubmed: 36302750
Elife. 2016 Aug 19;5:
pubmed: 27542194
Mol Imaging Biol. 2018 Aug;20(4):575-583
pubmed: 29374343
J Biochem. 1986 Jun;99(6):1765-72
pubmed: 3091586
Science. 2018 May 4;360(6388):508-513
pubmed: 29724949
Methods Cell Biol. 2010;99:1-26
pubmed: 21035681
Mol Pharmacol. 2009 Feb;75(2):281-95
pubmed: 18955585
Front Physiol. 2013 Dec 17;4:370
pubmed: 24381558
J Phys Chem B. 2014 May 15;118(19):5059-74
pubmed: 24779925
Annu Rev Pharmacol Toxicol. 2020 Jan 6;60:219-240
pubmed: 31337271
J Pharmacol Sci. 2009 Jan;109(1):148-51
pubmed: 19129683
J Biomed Sci. 2018 May 24;25(1):46
pubmed: 29793480
Biophys J. 2007 Oct 1;93(7):2307-14
pubmed: 17545243
Nat Chem Biol. 2014 Sep;10(9):753-9
pubmed: 25108821
Cancers (Basel). 2022 Jul 22;14(15):
pubmed: 35892822
Crit Care Med. 1994 Oct;22(10):1550-6
pubmed: 7924364
Front Pharmacol. 2020 Feb 28;11:143
pubmed: 32184726
Immunol Rev. 2009 Sep;231(1):59-87
pubmed: 19754890
PLoS One. 2018 Jun 28;13(6):e0199942
pubmed: 29953543
BMC Syst Biol. 2008 Jun 02;2:48
pubmed: 18518982
Neuron. 2004 Sep 16;43(6):847-58
pubmed: 15363395
Sci Rep. 2018 Apr 12;8(1):5937
pubmed: 29650988
Curr Neuropharmacol. 2018;16(5):608-617
pubmed: 28875832
J Cell Sci. 2017 Feb 15;130(4):663-669
pubmed: 28202602
Biol Futur. 2021 Mar;72(1):75-83
pubmed: 34554500
Front Immunol. 2022 Oct 05;13:997621
pubmed: 36275686
Commun Biol. 2019 Apr 26;2:144
pubmed: 31044169
Nat Metab. 2023 Feb;5(2):314-330
pubmed: 36717749
EMBO Rep. 2006 Oct;7(10):1006-12
pubmed: 16936637
Assay Drug Dev Technol. 2013 Nov-Dec;11(9-10):551-60
pubmed: 24351043
J Neurosci. 2007 Feb 28;27(9):2369-76
pubmed: 17329434
Nature. 2016 Sep 22;537(7621):497-499
pubmed: 27626384
Cell Mol Biol Lett. 2007;12(2):220-30
pubmed: 17160583
Acta Pharm Sin B. 2021 Aug;11(8):2243-2264
pubmed: 34522586
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8151-6
pubmed: 10884437
Rep Biochem Mol Biol. 2019 Jul;8(2):139-146
pubmed: 31832437
J Membr Biol. 2002 May 1;187(1):71-9
pubmed: 12029379
Proc Natl Acad Sci U S A. 2022 Aug 23;119(34):e2202926119
pubmed: 35969786
Front Pharmacol. 2019 Sep 20;10:972
pubmed: 31616290
Cancer Res. 2012 Jun 1;72(11):2746-56
pubmed: 22593198
Curr Pharm Des. 2006;12(18):2199-220
pubmed: 16787250
Biol Chem. 2022 Dec 27;404(4):339-353
pubmed: 36571487
Jpn Dent Sci Rev. 2018 Feb;54(1):8-21
pubmed: 29628997
Sci Rep. 2014 Mar 19;4:4410
pubmed: 24642931
Nature. 2016 Sep 22;537(7621):539-543
pubmed: 27626381
Mol Cell. 2006 Dec 8;24(5):665-675
pubmed: 17157250
Int J Cancer. 2015 Sep 15;137(6):1306-17
pubmed: 25704182
Neuron. 1995 Nov;15(5):1169-81
pubmed: 7576659
J Neurosci Res. 1998 Jun 1;52(5):612-7
pubmed: 9632317
Channels (Austin). 2015;9(6):336-43
pubmed: 26217968
Oncoimmunology. 2022 May 1;11(1):2070337
pubmed: 35529677
Nature. 2009 Jul 30;460(7255):599-604
pubmed: 19641589
Sci Signal. 2018 Apr 24;11(527):
pubmed: 29692361
Trends Cancer. 2021 Aug;7(8):731-750
pubmed: 34074623
Semin Cancer Biol. 2017 Apr;43:74-89
pubmed: 28267587
J Biol Chem. 2000 Nov 24;275(47):37137-49
pubmed: 10961988
Biomimetics (Basel). 2019 Feb 27;4(1):
pubmed: 31105205
J Immunol. 2013 Dec 15;191(12):6273-80
pubmed: 24227782

Auteurs

Marco Cozzolino (M)

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Gyorgy Panyi (G)

Department of Biophysics and Cell Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.

Classifications MeSH